Cantor On MoonLake Immunotherapeutics - Initiates On Inexpensive Valuation, Strong Catalyst Path
Cantor On MoonLake Immunotherapeutics - Initiates On Inexpensive Valuation, Strong Catalyst Path
Cantor On MoonLake Immunoteutics——以低廉的估值和强劲的催化剂之路开
- Cantor Fitzgerald has initiated coverage on MoonLake Immunotherapeutics AG (NASDAQ:MLTX) with an Overweight rating and a price target of $23.
- MoonLake's lead program Sonelokimab or SLK (IL-17A & IL-17F nanobody), is currently in Phase 2 trials in Hidradenitis Suppurativa (HS-severe skin disease) and Psoriatic Arthritis (PsA).
- A more than $5 billion opportunity for SLK in HS is the primary driver of the analyst's bullish view.
- Also See: HC Wainwright Starts Coverage On This 'Best-In-Class Agent For Inflammatory Disorders.
- After recent positive phase 3 trials from competitor IL-17 injectables, Novartis AG's (NYSE:NVS) Cosentyx and UCB SA's (OTC:UCBJY) (OTC:UCBJF) Bimekizumab raise the analyst's confidence that SLK will work in HS and will likely raise the efficacy bar.
- Approval of IL-17 injectables over the next few years will significantly expand the HS market, and SLK could be a ~$1.5 billion drug.
- SLK is also de-risked in PsA. In September, FDA signed off Phase 2 study of sonelokimab for active psoriatic arthritis.
- This is a good entry point and timing for buying MLTX shares. The valuation is inexpensive relative to other immunology peers and has a strong catalyst path over the next 12 months.
- Price Action: MLTX shares are up 4.79% at $17.08 on the last check Tuesday.
- 坎托·菲茨杰拉德 已开始报道 MoonLake 免疫疗法 AG 纳斯达克股票代码：MLTX）的评级为增持，目标价为23美元。
- MoonLake的主要项目Sonelokimab或SLK（IL-17A 和 IL-17F 纳米抗体）目前正在化脓性汗腺炎（HS-严重皮肤病）和银屑病关节炎（PsA）进行2期试验。
- SLK在HS有超过50亿美元的机会是分析师看涨观点的主要驱动力。
- 另请参阅： HC Wainwright 开始报道这种 “一流的炎症性疾病药物”。
- 在竞争对手 IL-17 注射剂最近进行的 3 期试验呈阳性之后， 诺华股份公司 （纽约证券交易所代码：NVS）Cosentyx 和 UCB SA （场外交易代码：UCBJY）（场外交易代码：UCBJF）Bimekizumab提高了分析师对SLK将在HS起作用并可能提高疗效标准的信心。
- 在未来几年内，IL-17 注射剂的批准将显著扩大HS市场，而SLK可能成为一种约15亿美元的药物。
- SLK 在 pSa 中也降低了风险。9月，美国食品药品管理局签署了sonelokimab治疗活动性银屑病关节炎的2期研究。
- 这是购买MLTX股票的好切入点和时机。与其他免疫学同行相比，该估值便宜，并且在接下来的12个月中具有很强的催化作用。
- 价格走势： 周二的最后一张支票显示，MLTX股价上涨了4.79％，至17.08美元。